cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Madrigal Pharmaceuticals Inc
8 own
5 watching
Current Price
$194.38
$-10.27
(-5.02%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,515.92M
52-Week High
52-Week High
322.67001
52-Week Low
52-Week Low
119.76000
Average Volume
Average Volume
0.7M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization2,515.92M
icon52-Week High322.67001
icon52-Week Low119.76000
iconAverage Volume0.7M
iconDividend Yield--
iconP/E Ratio--
What does the Madrigal Pharmaceuticals Inc do?
Synta Pharmaceuticals Corp. focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its clinical stage drug candidate in oncology is ganetespib, an Hsp90 inhibitor, which is in Phase II clinical trials to evaluate the combination of ganetespib and paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma, including malignant peripheral nerve sheath tumors. The company's drug candidate in its Hsp90-inhibitor Drug Conjugate program is STA-12-8666, which is in preclinical trials for chemotherapy irinotecan. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.
Read More
How much money does Madrigal Pharmaceuticals Inc make?
News & Events about Madrigal Pharmaceuticals Inc.
Globe Newswire
10 months ago
Madrigal expects to complete full submission of the New Drug Application in July 2023 CONSHOHOCKEN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a...
Globe Newswire
10 months ago
First scientific presentation of detailed MAESTRO-NASH results confirms achievement of primary endpoints across multiple patient subgroupsNoninvasive imaging and biomarker data support findings on liver biopsy and demonstrate broad treatment response to resmetiromFurther analyses of results ...
Zolmax
10 months ago
Avoro Capital Advisors LLC grew its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL Get Rating) by 8.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,660,000 shares of ...
Fool.com Headlines
1 year ago
Two key tailwinds fueled a surge in the biotech's share price this week.Shares of clinical-stage biotech Madrigal Pharmaceuticals (NASDAQ: MDGL) rose by a noteworthy 20% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The ...
Zolmax
1 year ago
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL Get Rating) have received a consensus recommendation of Moderate Buy from the fourteen research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has ...
Frequently Asked Questions
Frequently Asked Questions
What is Madrigal Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Madrigal Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Madrigal Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Madrigal Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Madrigal Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Madrigal Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Madrigal Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Madrigal Pharmaceuticals Inc?
plus_minus_icon
What percentage is Madrigal Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Madrigal Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$194.38
$-10.27
(-5.02%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
$42.29
$-1.03 (-2.38 %)
SpringWorks Therapeutics Inc
SpringWorks Therapeutics Inc
$44.20
$0.82 (1.89 %)
Immunovant Inc
Immunovant Inc
$27.75
$-1.05 (-3.65 %)
Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc
$28.93
$-0.30 (-1.03 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
$42.29
$-1.03 (-2.38 %)
SpringWorks Therapeutics Inc
SpringWorks Therapeutics Inc
$44.20
$0.82 (1.89 %)
Immunovant Inc
Immunovant Inc
$27.75
$-1.05 (-3.65 %)
Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc
$28.93
$-0.30 (-1.03 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00